Current Trials and Studies

Part of the mission of The LAM Foundation is to fund promising research. Our researchers need your help in order to conduct their research. Please see the open protocols below to see if you meet any of the requirements and find out how you can participate.

Study of the Disease Process of LAM - National Institutes of Health

Dr. Joel Moss
CLICK HERE for more details.

Helen Green Research Travel Grant

Patients who are participating at the protocol at the NIH may be eligible to apply for the Helen Green Research Travel Grant. To learn more about the grant and the guidelines, check out the Helen Green Research Travel Fund Guidelines. You can apply for the grant by clicking here.

If you have any questions regarding this travel grant, please contact Anne McKenna, Patient Services & Education Manager at

Safety and Efficacy of Saracatinib in Subjects with Lymphangioleiomyomatosis (SLAM-2)

Dr. N. Tony Eissa at Baylor College of Medicine (main site for this multi-center study)
Women who are 18 years and older who have LAM are eligible to participate in this study. Subjects will be given 125 mg of saracatinib for up to nine months. The entire duration of the study is 12 months. Seven visits will be required throughout the study.

If you are interested in participating, please contact:

Caryn O. Pope, BSN, RRT, RCP
Clinical Research Coordinator
Baylor College of Medicine - Ben Taub General Hospital
(713) 873-2471 (office)
CLICK HERE for more details about the study.

COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC

David Kwiatkowski, Brigham and Women's Hospital
We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
CLICK HERE for more details.


Dr. Francis X. McCormack at University of Cincinnati
The Multi-Center International Durability and Safety of Sirolimus in Lymphangioleiomyomatosis (MIDAS) trial continues to recruit patients eager to contribute to LAM research. This study aims to follow women with LAM who are currently taking, have previously failed or been intolerant of, or are considering treatment with mTOR inhibitors sirolimus or everolimus as part of their clinical care. There are currently seven participating LAM clinics with more to come. Over 100 patients have signed consent with the University of Cincinnati with the intention to eventually transfer to their LAM clinic or choice.
CLICK HERE for more details